Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction.

Mueller-Hennessen, Matthias;Lindahl, Bertil;Giannitsis, Evangelos;Vafaie, Mehrshad;Mueller, Christian;et.al.
(2019) International Journal of Cardiology — Vol. 276, n° 1, p. 261-267 (2019)

Files

1-s20-S0167527318339214-main.pdf
  • Open Access
  • Adobe PDF
  • 728.55 KB

Details

Authors
  • Mueller-Hennessen, Matthias
    Author
  • Lindahl, Bertil
    Author
  • Giannitsis, Evangelos
    Author
  • Vafaie, Mehrshad
    Author
  • Author
  • Mueller, Christian
    Author
  • et. al.
Show more
Abstract
(en) BACKGROUND: We aimed to directly compare the diagnostic and prognostic performance of a dual maker strategy (DMS) with combined testing of copeptin and high-sensitivity (hs) cardiac troponin T (cTnT) at time of presentation with other algorithms for rapid rule-out of acute myocardial infarction (AMI). METHODS: 922 patients presenting to the emergency department with suspected AMI and available baseline copeptin measurements qualified for the present TRAPID-AMI substudy. Diagnostic measures using the DMS (copeptin <10, <14 or < 20 pmol/L and hs-cTnT≤14 ng/L), the 1 h-algorithm (hs-cTnT<12 ng/L and change <3 ng/L at 1 h), as well as the hs-cTnT limit-of-blank (LoB, <3 ng/L) and -detection (LoD, <5 ng/L) were compared. Outcomes were assessed as combined end-points of death and myocardial re-infarction. RESULTS: True-negative rule-out using the DMS could be achieved in 50.9%-62.3% of all patients compared to 35.0%, 45.3% and 64.5% using LoB, LoD or the 1 h-algorithm, respectively. The DMS showed NPVs of 98.1%-98.3% compared to 99.2% for the 1 h-algorithm, 99.4% for the LoB and 99.3% for the LoD. Sensitivities were 93.5%-94.8%, as well as 96.8%, 98.7% and 98.1%, respectively. Addition of clinical low-risk criteria such as a HEART-score ≤ 3 to the DMS resulted in NPVs and sensitivities of 100% with a true-negative rule-out to 33.8%-41.6%. Rates of the combined end-point of death/MI within 30 days ranged between 0.2% and 0.3% for all fast-rule-out protocols. CONCLUSION: Depending on the applied copeptin cut-off and addition of clinical low-risk criteria, the DMS might be an alternative to the hs-cTn-only-based algorithms for rapid AMI rule-out with comparable diagnostic measures and outcomes.
Affiliations

Citations

Mueller-Hennessen, M., Lindahl, B., Giannitsis, E., Vafaie, M., Biener, M., Haushofer, A. C., Seier, J., Christ, M., Alquézar-Arbé, A., deFilippi, C. R., McCord, J., Body, R., Panteghini, M., Jernberg, T., Plebani, M., Verschuren, F., French, J. K., Christenson, R. H., Dinkel, C., et al. (2019). Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. International Journal of Cardiology, 276(1), 261-267. https://doi.org/10.1016/j.ijcard.2018.10.084 (Original work published 2019)